Forte Biosciences, Inc. Income Statement
FBRX|2 years of annual SEC 10-K data (FY2018-FY2019)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
At a glance
Revenue
$41,000
FY2019
Gross Profit
N/A
FY2019
Operating Income
-$38M
FY2019
Net Income
-$39M
FY2019
Forte Biosciences, Inc. reported $41,000 in revenue and $39M in net loss for FY2019. Revenue decreased 16.3% from FY2018 to FY2019.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score NaN (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Currently unprofitable: Net income is negative
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2019 | FY2018 |
|---|---|---|
| Revenue | $41.0K | $49.0K |
| SG&A Expense | $8.6M | $4.5M |
| R&D Expense | $29.1M | $27.2M |
| Operating Income | -$37.6M | -$31.7M |
| Interest Expense | $1.9M | $2.1M |
| Income Tax | $1.0K | $1.0K |
| Net Income | -$38.9M | -$33.5M |
| EPS (Diluted) | -$2.66 | -$15.22 |
| Shares Outstanding | 23.0M | 19.9M |
| Operating Margin | -91775.6% | -64673.5% |
| Profit Margin | -94948.8% | -68322.4% |